The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Stem Cells Spin's Revenue for the
three
months ended in Mar. 2026 was zł0.01 Mil. Stem Cells Spin's average Accounts Receivable for the
three
months ended in Mar. 2026 was zł0.01 Mil.
Hence, Stem Cells Spin's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.52.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Stem Cells Spin Receivables Turnover Related Terms
Stem Cells Spin Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Stem Cells Spin's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SCS vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Stem Cells Spin's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Cells Spin Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stem Cells Spin's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Stem Cells Spin's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stem Cells Spin (WAR:SCS) has a Receivables Turnover of 0.52 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Stem Cells Spin and its competitors. According to the industry distribution chart, Stem Cells Spin ranks #660 out of 841 companies in the Biotechnology industry, placing it in the top 78.5%.
Is Stem Cells Spin's Receivables Turnover too high?
Stem Cells Spin's current Receivables Turnover is 0.52. The Biotechnology industry median Receivables Turnover is 5.29. Stem Cells Spin's value of 0.52 is 90.2% below this industry median. Based on the distribution chart, Stem Cells Spin ranks #660 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stem Cells Spin has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #660 out of 841 companies for Receivables Turnover. This places Stem Cells Spin in the lower half of its industry. The industry median Receivables Turnover is 5.29. Stem Cells Spin's value of 0.52 is 90.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stem Cells Spin's current Receivables Turnover of 0.52 is 90.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Stem Cells Spin and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Cells Spin's current Receivables Turnover is 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.37 — trading 274% above its estimated fair value. The current Receivables Turnover is 0.52 and 90.2% below the Biotechnology industry median of 5.29. Stem Cells Spin's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current Receivables Turnover is 0.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?
Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued.
The current stock price of zł0.37 is trading 274% above its estimated GF Value™ of zł0.10.
GuruFocus considers Stem Cells Spin to be Significantly Overvalued.
Key valuation signals for WAR:SCS:
Receivables Turnover: 0.52
GF Value™: zł0.10 vs. price of zł0.37 (274% above fair value)
Industry Position: 90.2% below the Biotechnology median (#660 of 841)
No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
26GF Score
Get the complete analysis for WAR:SCS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCS has been successfully added to your 
